Alector, Inc.
ALECHealthcare|Biotechnology|US
$2.29
+0.20 (+9.57%)
Tangible Book / Share
$1.05
Graham Number
$2.96
Cash / Share
$1.25
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07105709 Open-label Extension Study in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P2 | Recruiting | 220 | Open-label | GSK4527226 |
| NCT04374136 A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Frontotemporal Dementia | P3 | Terminated | 119 | RCT, Double-blind | Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001 |
| NCT06111014 Continuation Study for Latozinemab | Neurodegenerative Diseases | P3 | Terminated | 17 | Open-label | Latozinemab |
| NCT05053035 A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Amyotrophic Lateral Sclerosis | P2 | Terminated | 5 | RCT, Double-blind | AL001, Placebo |
| NCT03987295 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Frontotemporal Dementia | P2 | Completed | 33 | Open-label | AL001 |
| NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | Alzheimer Disease | P2 | Completed | 356 | RCT, Double-blind | AL002, Placebo |
| NCT06079190 Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P2 | Terminated | 367 | RCT, Double-blind | GSK4527226 |
| NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease | Alzheimer's Disease | P2 | Terminated | 197 | RCT, Double-blind | AL002 |
| NCT03822208 First in Human Study for Safety and Tolerability of AL003. | Healthy, Alzheimer Disease | P1 | Completed | 54 | RCT, Double-blind | AL003 |
| NCT03636204 A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation | Healthy, Frontotemporal Dementia | P1 | Completed | 64 | RCT, Double-blind | AL001 |
| NCT03635047 A Phase I Study for Safety and Tolerability of AL002. | Healthy, Alzheimer Disease | P1 | Completed | 69 | RCT, Double-blind | AL002 |
| NCT04111666 A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | Healthy | P1 | Completed | 88 | RCT, Double-blind | AL101 |